Welcome to LookChem.com Sign In|Join Free
  • or
[1-(2-Hydroxy-ethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

153826-05-2

Post Buying Request

153826-05-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

153826-05-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 153826-05-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,8,2 and 6 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 153826-05:
(8*1)+(7*5)+(6*3)+(5*8)+(4*2)+(3*6)+(2*0)+(1*5)=132
132 % 10 = 2
So 153826-05-2 is a valid CAS Registry Number.

153826-05-2Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors

Qiao, Zhitao,Wang, Weiwei,Wang, Lie,Wen, Donghua,Zhao, Yaxue,Wang, Qing,Meng, Qingqing,Chen, Guoqiang,Wu, Yingli,Zhou, Huchen

, p. 6389 - 6392 (2011/11/29)

As the best-characterized ubiquitin-like protein (UBL), small ubiquitin-related modifier (SUMO) was found to conjugate with a number of proteins to regulate cellular functions including transcription, signal transduction, and cell cycle. While E1, E2 and E3 ligases are responsible for the forward SUMOylation reaction, SUMO-specific proteases (SENPs) reversibly removeSUMOfrom the SUMOylated proteins. Recently, SENP1 was found to be a potential therapeutic target for the treatment of prostate cancers, but the design and synthesis of its inhibitors have not been reported. We designed and synthesized a series of benzodiazepinebased SENP1 inhibitors, and they showed inhibitory activity as good as IC50 = 9.2 μM (compound 38). The structure-activity relationship was also discussed.

Development of 1,4-Benzodiazepine Cholecystokinin Type B Antagonists

Bock, Mark G.,DiPardo, Robert M.,Evans, Ben E.,Rittle, Kenneth E.,Whitter, Willie L.,et al.

, p. 4276 - 4292 (2007/10/02)

A series of 3-(arylureido)-5-phenyl-1,4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK), are described.Derived by reasoned modification of the CCK-A selective 3-carboxamido-1,4-benzodiazepine, MK-329, this paper chronicles the development of potent, orally effective compounds in which selectivity for the CCK-B recebtor subtype was achieved.The principal lead structure that emerged from these studied is L-365,260, a compound which has been submitted for clinical evaluation.Details of the ability to modulate the receptor interactions of these benzodiazepines by appropriate structure modifications are discussed which imply the possibility of further refining the CCK-B receptor affinity and selectivity of this class of compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 153826-05-2